莫德納

The American pharmaceutical company Moderna and its partner Merck jointly announced a major medical breakthrough on the 19th. The experimental mRNA personalized cancer vaccine "intismeran" jointly developed by the two parties successfully prevented the recurrence and spread of high-risk melanoma in late-stage clinical trials, bringing new hope to patients to extend their lives. The late-stage clinical trial is testing intismeran in combination with Merck's best-selling anti-cancer immune system